Lantheus Medical Imaging parent company Lantheus Holdings has agreed to supply its microbubble ultrasound contrast technology to medical device company CarThera for the treatment of glioblastoma.
The commercial supply agreement gives CarThera the rights to include Lantheus' microbubble ultrasound technology as a component of CarThera's SonoCloud intracranial ultrasound implant. SonoCloud uses low-intensity pulsed ultrasound to open the blood-brain barrier and thereby facilitate the delivery of chemotherapy to brain tumors.
Per the agreement, CarThera will be responsible for all regulatory filings and approvals, as well as for the commercialization of SonoCloud. Lantheus is set to receive royalties on SonoCloud product sales upon device approval.
The latest version of CarThera's ultrasound implant, SonoCloud-9, is currently undergoing evaluation as part of a phase IIa clinical trial conducted at various institutions in France and the U.S.
